診斷和監(jiān)測(cè)帕金森病進(jìn)展的生物標(biāo)志物甚為需要,，目前,，大部分的研究集中在α-突觸核蛋白 (α-Syn),。它是一種涉及帕金森病發(fā)病機(jī)理的蛋白質(zhì),，作為一種潛在的生物標(biāo)志物,，有時(shí)與臨床結(jié)果并不一致,。近期在帕金森病患者的血清中檢測(cè)到了自身存在的抗α-Syn自身抗體,。馬爾堡菲利普大學(xué)神經(jīng)科的Daniela Besong-Agbo博士等人進(jìn)行了一項(xiàng)研究,，研究結(jié)果在線發(fā)表在2012年12月19日的Neurology雜志上。研究結(jié)果發(fā)現(xiàn)：相較AD患者與健康對(duì)照人群,，帕金森病患者的α-Syn-nAbs水平降低,。
研究人員建立并驗(yàn)證了血清標(biāo)本量化檢測(cè)的α-Syn 自然發(fā)生自身抗體（α-Syn-nAbs）的ELISA法。使用這種新建的ELISA方法分析來(lái)自62位帕金森病患者的血清標(biāo)本和46位健康對(duì)照（HC）及42位阿爾茨海默?。ˋD）患者,。另外，還測(cè)定了血清內(nèi)源性α-Syn水平,。
研究結(jié)果顯示：各觀察組α-Syn-nAbs 水平存在顯著差異(p = 0.005; Kruskal-Wallis測(cè)試法),。相較正常對(duì)照組(p < 0.05; Dunn多重比較)和AD患者(p < 0.05)，帕金森病患者的α-Syn-nAbs 水平顯著較低,。
該研究發(fā)現(xiàn)：使用驗(yàn)證良好的方法,，相較AD患者與健康對(duì)照人群，帕金森病患者的α-Syn-nAbs水平降低,。該方法還無(wú)法用作可靠區(qū)分帕金森病與健康對(duì)照的可靠工具,。需要進(jìn)一步的研究評(píng)估α-Syn-nAbs能否作為帕金森病患者的一個(gè)生物標(biāo)志物。(生物谷Bioon.com)
DOI:10.1212/WNL.0b013e31827b90d1
PMC:
PMID:
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease
Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, Reindl M, Oertel WH, Noelker C, Bacher M, Dodel R.
OBJECTIVE:Biomarkers are required for the diagnosis and monitoring of disease progression in Parkinson disease (PD). To date, most studies have concentrated on α-synuclein (α-Syn), a protein involved in Parkinson disease pathogenesis, as a potential biomarker, with inconsistent outcomes. Recently, naturally occurring autoantibodies against α-Syn (α-Syn-nAbs) have been detected in the serum of patients with PD. They represent a putative diagnostic marker for PD. METHODS:We established and validated an ELISA to quantify α-Syn-nAbs in serum samples. We analyzed serum samples from 62 patients with PD, 46 healthy controls (HC), and 42 patients with Alzheimer disease (AD) using this newly established ELISA. Additionally, serum levels of endogenous α-Syn were measured. RESULTS:There was a significant difference in α-Syn-nAbs levels between the investigated groups (p = 0.005; Kruskal-Wallis test). Levels of α-Syn-nAbs were significantly lower in patients with PD compared to HC (p < 0.05; Dunn multiple comparison post hoc test) or patients with AD (p < 0.05). Furthermore, we detected no difference between patients with AD and HC. The sensitivity and specificity of the assay for patients with PD vs HC were 85% and 25%, respectively. The α-Syn-nAbs levels did not correlate with age, Hoehn & Yahr status, or duration of disease. Endogenous α-Syn had no influence on α-Syn-nAbs levels in sera. CONCLUSIONS:Using a well-validated assay, we detected reduced α-Syn-nAbs levels in patients with PD compared to patients with AD and HC. The assay did not achieve criteria for use as a diagnostic tool to reliably distinguish PD from HC. Further studies are needed to assess α-Syn-nAbs as a biomarker in PD
